At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
botulinum toxin, Type A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
In Brief
A Phase 2 clinical trial evaluating botulinum toxin, Type A and Vehicle for Lateral Canthal Lines and Crow's Feet. Completed, enrolled 48 participants across 1 site.
Detailed Summary
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Canthal Lines, Crow's Feet
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedOct 2017
Primary CompletionJun 2018
Study CompletionNov 2018
TodayJul 2026
First PostedOct 31, 2017
Enrollment StartOct 25, 2017
Primary CompletionJun 11, 2018
Study CompletionNov 14, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.7 years ago
Interventions
botulinum toxin, Type Abiological
topical liniment
Vehiclebiological
Vehicle Formulation